Polaris Group
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
May 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 5, 2027The maintenance fee for Engineered chimeric pegylated ADI and methods of use (US 10,463,721) comes due May 5, 2027. Unpaid by Nov 5, 2027, it lapses early.
- 1 fee due Jul 7, 2027The maintenance fee for Methods of treatment with arginine deiminase (US 10,525,142) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
- 1 fee due Nov 10, 2027The maintenance fee for Methods of treatment with arginine deiminase (US 9,333,268) comes due Nov 10, 2027. Unpaid by May 10, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,333,268 | Methods of treatment with arginine deiminase In force · From the USPTO record | In force | From the USPTO record | |
| US 10,525,142 | Methods of treatment with arginine deiminase In force · From the USPTO record | In force | From the USPTO record | |
| US 9,731,028 | Methods of treatment with arginine deiminase In force · From the USPTO record | In force | From the USPTO record | |
| US 11,235,037 | Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies for cancer treatment In force · From the USPTO record | In force | From the USPTO record | |
| US 9,938,355 | Antibodies to argininosuccinate synthase and related methods In force · From the USPTO record | In force | From the USPTO record | |
| US 9,789,170 | Arginine deiminase with reduced cross-reactivity toward ADI-PEG 20 antibodies for cancer treatment In force · From the USPTO record | In force | From the USPTO record | |
| US 10,463,721 | Engineered chimeric pegylated ADI and methods of use In force · From the USPTO record | In force | From the USPTO record | |
| US 12,281,339 | Combination Cancer Immunotherapies with Arginine Depletion Agents In force · High confidence | In force | High confidence | |
| US 12,370,242 | Formulations of pegylated arginine deiminase In force · From the USPTO record | In force | From the USPTO record | |
| US 12,344,645 | Protein conjugates In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 10: 1 lapsed for an unpaid fee · 7 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 4 no status recorded